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variances. RESULTS: Data were available for 1669 employees
with FD and a control group of (274,206) employees without
FD. The FD group’s costs (per employee/year) were twice as high
($3676) summed across all direct medical and work absence
measures (P < 0.0001). The individual differences (favoring FD)
in medical and pharmacy costs were $3420 and $365, respec-
tively (both P < 0.0001). Work absence costs had differences of
$103 (SL, P < 0.0001), $104 (STD, P = 0.0370), $7 (LTD, P =
0.6551). Measured units of productivity were 2 units less/hour
with the FD group (P = 0.055). CONCLUSION: This study con-
ﬁrms earlier work from Sweden, but shows that in the US, FD
can be costly to employers. Physicians and patients need more
education on the ROME II criteria and how to integrate this
information into improving medical and pharmaceutical costs.
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OBJECTIVES: The risk of gastrointestinal ulcers is enhanced by
non-steroidal anti-inﬂammatory drugs (NSAID). Proton pump
inhibitors (PPI) are used for gastroprotection, but their effec-
tiveness has been documented only in few studies (Hooper et al.
BMJ 2004; 329:948–57). We therefore investigated in the gas-
troprotective effects of PPI on diclofenac-induced ulcer risk.
METHODS: A nested case control study was performed based
on claims data from a large German sickness fund. A cohort was
constructed consisting of all beneﬁciaries enrolled in the health
plan continuously from 2000 until 2004. Cases had an inpatient
treatment due to peptic ulcer starting at or after January 1st 2003
with the case onset being the index date. All other beneﬁciaries
were randomly allocated to an index date, and ten controls per
case were drawn. For the 90 days before the index date it was
checked, if diclofenac and/or PPI were dispensed. The inﬂuence
of diclofenac alone as well as with concomitant PPI prescription
on ulcer risk was analysed using logistic regression models.
RESULTS: We identiﬁed 979 cases and 10,319 controls in the
cohort of 752,613 beneﬁciaries. The stratiﬁed analysis accord-
ing to the prescription of diclofenac alone or in combination with
PPI showed that diclofenac prescriptions within the 90 days
before the index day increased the risk for hospitalization due 
to peptic ulcer signiﬁcantly (odds ratio (OR) 3.21; 95%CI
2.59–3.96; p < 0.001). The risk was reduced (OR 1.26; 95%CI
0.68–2.30; p = 0.46), if PPI were prescribed concomitantly with
diclofenac. The signiﬁcance of the PPI effect was demonstrated
by inserting an interaction term in a regression model without
stratiﬁcation, where a risk reduction of 63% (OR 0.37; 95%CI
0.18–0.74; p = 0.005) was found. CONCLUSION: The con-
comitant prescription of PPI and diclofenac decreases the hospi-
talization risk due to peptic ulcer thus supporting the use of PPI
as gastroprotective agents.
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OBJECTIVES: To conduct an economic evaluation of terli-
pressin and octreotide used in the UK in the treatment of Bleed-
ing Oesophageal Varices (BOV). METHODS: Efﬁcacy results
from Cochrane meta-analyses were used. Baseline course of
disease and health-related utility (HRU) were retrieved from
published sources. Hospitalization related data were extracted
from HODaR, a large longitudinal database. Costs were
obtained from published sources, BNF and HODaR. A discrete
event simulation model was coded in VBA with the following
transition states: bleeding, no bleeding, no bleeding post-TIPS,
post-salvage surgery, and death. Weibull curves were ﬁtted to
estimate baseline survival, re-bleeding rates, and failure to
control bleeding. Simulations were run for up to ﬁve years since
initial bleeding. Prices were in UK£2005 and a discount rate of
3.5% was applied to costs and beneﬁts. Sensitivity analysis was
run with C++ dll engine. RESULTS: Terlipressin was found 
to be cost-effective with baseline values of ICER at 1 year
£5263/QALY (£3865/LYG) versus octreotide and £5618/QALY
(£4136/LYG) versus placebo. In baseline analysis octreotide was
not cost-effective against placebo. Based on deterministic and
probabilistic sensitivity analyses terlipressin remained cost-effec-
tive when compared to octreotide and placebo; it was cost-saving
for some of the varied input values. Distribution of ICER values
demonstrated cost-effectiveness of octreotide versus placebo, but
on CEAC curve, probability of cost-effectiveness of octreotide
and placebo were of the same magnitude: 24.0% and 23.4%,
respectively, at £20,000/QALY. The results were sensitive to
utility variables, but were generally robust and independent of
assumptions regarding baseline risk. Total Expected Value of
Perfect Information at 1 year varied from £928 to £220 per
patient depending on the range of variation of input variables.
CONCLUSIONS: Terlipressin is cost-effective when compared
to octreotide and placebo for the treatment of BOV in cirrhotic
patients. Further analysis is needed to establish cost-effectiveness
of octreotide versus placebo.
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OBJECTIVES: To assess the cost-effectiveness of two commonly
used triple therapies for H. pylori eradication in a public hospi-
tal in Hong Kong. METHODS: A prospective observational
design was adopted. Two cohorts of patients attending the GI
Specialty Clinic at the Prince of Wales Hospital with endoscop-
ically conﬁrmed non-ulcer dyspepsia and H. pylori positive con-
ﬁrmed by CLO Test were recruited. Informed consent from
patients and ethic approval from hospital were obtained. The
patients were consecutively recruited to receive esomeprazole +
amoxicillin + clarithromycin (EAC) or rabeprazole + amoxicillin
+ clarithromycin (RAC) therapies. One-week treatment was
given and urea breath test was performed after 4 weeks to
conﬁrm if eradication was successful. Initial treatment failures
were given quadruple rescue therapy (metronidazole + esomepra-
zole + danol + tetracycline). All health care resources including
clinic visits, laboratory procedures, medications, and profes-
sional services were recorded. RESULTS: One-hundred and three
and 96 patients were recruited to the EAC and RAC groups
respectively. The demographic characteristics were not signiﬁ-
cantly different except the RAC group had a lower rate of drink-
ing and smoking habits. The success rates for eradication for the
EAC and RAC groups were 88.5% and 85.4% respectively (p =
NS). The cost/successful eradication for EAC group and RAC
group was USD846 and USD843.7 respectively. The cost/suc-
cessful eradication after quadruple therapy was USD871 and
